Gliomas are the major type of primary brain tumors. Accumulating research has demonstrated that tubulin is connected with the development and malignant progression of tumors. TUBA1C is a subtype of α-tubulin and is linked to prognosis in multiple cancers. In this study, the prognosis-related gene TUBA1C in glioma was identified and analyzed by bioinformatic approaches such as Kaplan–Meier (KM) survival time analysis, univariate and multivariate Cox analysis, receiver operating characteristic (ROC) analysis and functional enrichment analysis. Based on the above analyses, we found that glioma tissues had significantly higher expression of TUBA1C than normal brain tissues, and high expression of TUBA1C has worse prognosis in glioma. Gene set enrichment analysis (GSEA) revealed the signaling pathways related to the cell cycle. Furthermore, knockdown of TUBA1C also inhibited proliferation and migration and caused apoptosis and G2/M phase arrest in glioma cells. This study demonstrated that high TUBA1C expression correlated with poor outcomes in glioma patients and that knocking down TUBA1C suppressed glioma cell proliferation via cell cycle arrest. In addition, TUBA1C might be a therapeutic biomarker for gliomas.

胶质瘤是原发性脑肿瘤的主要类型。越来越多的研究表明，微管蛋白与肿瘤的发生和恶性进展有关。TUBA1C 是 α-微管蛋白的一个亚型，与多种癌症的预后有关。本研究通过Kaplan-Meier (KM)生存时间分析、单变量和多变量Cox分析、受试者工作特征(ROC)分析和功能富集分析等生物信息学方法鉴定和分析胶质瘤中预后相关基因TUBA1C。综合以上分析，我们发现胶质瘤组织中TUBA1C的表达明显高于正常脑组织，且TUBA1C高表达在胶质瘤中预后较差。基因集富集分析（GSEA）揭示了与细胞周期相关的信号通路。此外，TUBA1C 的敲低还抑制了增殖和迁移，并导致神经胶质瘤细胞的细胞凋亡和 G2/M 期停滞。该研究表明，高 TUBA1C 表达与神经胶质瘤患者的不良预后相关，并且敲低 TUBA1C 可通过细胞周期停滞抑制神经胶质瘤细胞增殖。此外，TUBA1C 可能是胶质瘤的治疗生物标志物。